Insider Selling: SOPHiA GENETICS (NASDAQ:SOPH) CFO Sells 1,592 Shares of Stock

Posted by Francis Steltz on Oct 7th, 2026

SOPHiA GENETICS SA (NASDAQ:SOPH – Get Free Report) CFO George Cardoza sold 1,592 shares of the company’s stock in a transaction on Monday, October 5th. The stock was sold at an average price of $8.10, for a total value of $12,895.20. Following the transaction, the chief financial officer directly owned 306,726 shares in the company, valued at $2,484,480.60. This represents a 0.52% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

George Cardoza also recently made the following trade(s):

On Monday, September 21st, George Cardoza sold 774 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $8.33, for a total value of $6,447.42.

SOPHiA GENETICS Price Performance

Shares of NASDAQ SOPH traded down $0.23 during trading on Wednesday, hitting $7.15. 432,750 shares of the company were exchanged, compared to its average volume of 308,157. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.69 and a quick ratio of 2.55. SOPHiA GENETICS SA has a 1 year low of $3.75 and a 1 year high of $8.98. The company has a market cap of $599.81 million, a price-to-earnings ratio of -6.22 and a beta of 0.95. The firm’s fifty day moving average price is $7.82 and its 200 day moving average price is $6.12.

SOPHiA GENETICS (NASDAQ:SOPH – Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.05). SOPHiA GENETICS had a negative net margin of 93.86% and a negative return on equity of 132.47%. The company had revenue of $23.31 million during the quarter, compared to analysts’ expectations of $21.72 million. On average, sell-side analysts expect that SOPHiA GENETICS SA will post -0.77 earnings per share for the current fiscal year.

SOPHiA GENETICS News Summary

Here are the key news stories impacting SOPHiA GENETICS this week:

Positive Sentiment: Brokerages reportedly have a consensus price target of $10.00 for SOPHiA GENETICS, suggesting potential upside from recent trading levels if the company meets analyst expectations. SOPHiA GENETICS SA Stock Has Consensus Target Price of $10.00 According to Brokerages
Neutral Sentiment: A comparison article examined SOPHiA GENETICS against Weave Communications, but the item did not identify a specific new company development or change to SOPH’s outlook. Critical Comparison: Weave Communications vs. SOPHiA GENETICS
Negative Sentiment: Company insiders collectively sold approximately 82,298 shares worth $668,827, including sales by Chairman Jurgi Camblong, CEO Ross Muken, CFO George Cardoza, CTO Abhimanyu Verma and other executives. The transactions reduced their individual holdings by roughly 0.15% to 3.55%, creating near-term selling pressure and potentially weighing on investor sentiment. However, all reported sales were pre-arranged and explicitly made to satisfy tax obligations rather than indicating discretionary selling. SEC insider transaction filing

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on SOPH shares. BTIG Research lifted their price objective on SOPHiA GENETICS from $8.00 to $9.00 and gave the stock a “buy” rating in a report on Wednesday, August 5th. Weiss Ratings reiterated a “sell (d-)” rating on shares of SOPHiA GENETICS in a research report on Friday, July 17th. Zacks Research raised shares of SOPHiA GENETICS to a “hold” rating in a research note on Tuesday, July 21st. Finally, HC Wainwright raised their target price on shares of SOPHiA GENETICS from $12.00 to $14.00 and gave the company a “buy” rating in a report on Wednesday, August 5th. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, SOPHiA GENETICS has an average rating of “Hold” and an average price target of $10.00.

Read Our Latest Research Report on SOPHiA GENETICS

Institutional Trading of SOPHiA GENETICS

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. AWM Investment Company Inc. purchased a new position in SOPHiA GENETICS in the 2nd quarter valued at about $9,809,000. Hodges Capital Management Inc. purchased a new stake in shares of SOPHiA GENETICS during the first quarter worth about $2,157,000. Sei Investments Co. acquired a new position in shares of SOPHiA GENETICS in the first quarter valued at approximately $1,772,000. Maven Securities LTD acquired a new position in shares of SOPHiA GENETICS in the second quarter valued at approximately $866,000. Finally, Hennion & Walsh Asset Management Inc. purchased a new position in shares of SOPHiA GENETICS during the second quarter valued at approximately $567,000. Hedge funds and other institutional investors own 31.59% of the company’s stock.

About SOPHiA GENETICS

(Get Free Report)

SOPHiA GENETICS is a healthcare technology company that develops cloud-based data analytics solutions for the life sciences and healthcare industries. Its platform is designed to help organizations analyze and interpret complex genomic and multimodal data to support more informed clinical and research decisions.

The company’s principal offering, the SOPHiA DDM platform, combines data management, analytics and artificial intelligence capabilities. It supports applications including cancer genomics, hereditary disease analysis, reproductive health and other areas of precision medicine.